The estimated Net Worth of Mark R E Pinney is at least $2.84 Milione dollars as of 13 November 2006. Mark Pinney owns over 15,713 units of Acorda Therapeutics Inc stock worth over $1 and over the last 18 years Mark sold ACOR stock worth over $2,840,461.
Mark has made over 3 trades of the Acorda Therapeutics Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently Mark sold 15,713 units of ACOR stock worth $234,752 on 13 November 2006.
The largest trade Mark's ever made was selling 115,221 units of Acorda Therapeutics Inc stock on 16 October 2006 worth over $1,876,950. On average, Mark trades about 58,165 units every 9 days since 2006. As of 13 November 2006 Mark still owns at least 1 units of Acorda Therapeutics Inc stock.
You can see the complete history of Mark Pinney stock trades at the bottom of the page.
Mark's mailing address filed with the SEC is 15 SKYLINE DRIVE, , HAWTHORNE, NY, 10532.
Over the last 19 years, insiders at Acorda Therapeutics Inc have traded over $155,173,492 worth of Acorda Therapeutics Inc stock and bought 1,139,691 units worth $17,085,546 . The most active insiders traders include Capital Management Lp Scopi..., Ian F Smith e Ron Cohen. On average, Acorda Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of $19,752. The most recent stock trade was executed by Ron Cohen on 16 March 2023, trading 20,156 units of ACOR stock currently worth $12,497.
acorda therapeutics is a publicly traded (nasdaq: acor) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders. we started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders. we have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. we achieve our goals by: • investing in research and development • collaborating closely with the patient, medical and scientific communities • retaining employees with compassion and commitment acorda has been voted one of the best companies to work for in new york for the past five years in a row, as a result of our dynamic environment, strong corporate
Acorda Therapeutics Inc executives and other stock owners filed with the SEC include: